Archive for the "Patent News" Category

31
Jul

 

Medical Patent News

Wyeth and Impax Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to Impax’s proposed generic capsule formulation of Wyeth’s Effexor XR antidepressant have been approved by the United States District Court for the District of Delaware.

The Court entered a consent judgment resulting in termination of the litigation effective today.

Under the terms of the settlement, Wyeth has granted Impax a license that would permit Impax to launch its capsule formulation of Effexor XR on or after June 1, 2011, subject to earlier launch in limited circumstances, but in no event earlier than January 1, 2011. Impax will pay Wyeth a royalty on sales of this generic product.

The parties also have agreed that Impax will utilize its neurology-focused sales force to promote a product to be named by Wyeth. Other terms of this agreement are confidential and were not disclosed.

http://www.wyeth.com

31
Jul

 

Medical Patent News

Major drugs companies are using fierce lobbying tactics to protect a pharmaceutical patent system that is “simply morally unacceptable”, a world-leading political philosopher will tell a major meeting of UK and European pharmacologists today (Thursday 17 July 2008).

Addressing an audience that will include senior figures from the pharmaceutical industry, Thomas Pogge, Professor of Philosophy and International Affairs at Yale University in the United States, will argue that international rules on intellectual property “violate the human rights of poor people by denying them access to vital medicines”.

He will go on to say that huge mortality and morbidity rates can be dramatically lowered by reforming the way the development of new medical treatments is funded.

In his AstraZeneca-sponsored lecture entitled, ‘Advanced Medicines: Must We Exclude the Global Poor?’, Pogge will propose an alternative licensing system called the Health Impact Fund (HIF) which he says is “required as an add-on to the existing system to render it human-rights compliant”.

The HIF would be a global agency, says Pogge, underwritten by governments. It would offer to reward the patentee of any new medicine, during its first decade or so, with annual payments proportional to this medicine’s demonstrated global health impact.

Registering a medicine with the Fund would be voluntary and require a concession affecting its price. Pogge says this would give innovators the opportunity to forgo “monopoly rents in favour of an alternative path that would provide ample rewards for the development of new high-impact medicines without excluding the poor from their use”.

Pogge will deliver his AstraZeneca-sponsored lecture on the final day of the Federation of European Pharmacological Societies (EPHAR) 2008 Congress, hosted by the British Pharmacological Society at The University of Manchester.

Speaking ahead of his lecture, Pogge said: “The main responsibility for change lies with politicians and citizens. But pharmaceutical companies are also citizens, and they play a significant role in the political process of most societies. They lobby a lot. And here I do see fault. They lobby for holding the line on a status quo that is simply morally unacceptable.

“They do this because they know the existing rules can have a profitable business model under them and are uncertain what alternative rules would be settled upon once the existing rules were found unacceptable.

“I want to change this conservative attitude. I want to give them an institutional reform that they can endorse and unite behind. I am convinced they would do better, on the whole, with the Health Impact Fund than without. I want to convince them of this. And I want to show them that, on balance, they have more to gain than to lose by supporting this reform.

“It will be harder and harder to hold the line on the existing system, and the HIF reform preserves pretty much everything they like about this system. In other words, they have both moral and strategic reasons to support the HIF.”

Pogge’s lecture is expected to provoke fierce debate at the conference, with many delegates holding alternative views.

http://www.manchester.ac.uk/

26
Jul

 

Medical Patent News

The Brazilian group Interdisciplinary AIDS Association, or ABIA, has joined Indian patient advocacy groups to oppose a patent application for Gilead Science’s antiretroviral drug Tenofovir, saying that the patent would have a direct impact width=396 align=left vspace=5 border=0>This article is republished with kind permission from our friends at The Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, debates and discussions. The Kaiser Daily Health Policy Report is published for Kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. Copyright 2008 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

26
Jul

 

Medical Patent News

India’s Patent Office in New Delhi earlier this month rejected German drug maker Boehringer Ingelheim’s application for a pediatric version of the antiretroviral drug nevirapine, consequently allowing local generic pharmaceutical companies such as Aurobindo and Cipla to continue marketing low-cost versions of the medicine in the domestic market, the Business Standard reports.

The decision follows objections to the potential patent from civil society groups in the country (Mathew, Business Standard, 6/20).

According to the Lawyer’s Collective, a New Delhi-based socio-legal group, this is the first decision width=396 align=left vspace=5 border=0>This article is republished with kind permission from our friends at The Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, debates and discussions. The Kaiser Daily Health Policy Report is published for Kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. Copyright 2008 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

26
Jul

 

Medical Patent News

Alchemia Ltd. has announced the granting of the first two patents in the “Synthetic Heparin Oligosaccharide” family of patents.

Australian patent 2002331426 and divisional patent 2007203325 were recently sealed by IP Australia. A further two divisional applications (2008200767 and 2008200716) have completed the examination process and have been accepted to grant. Both of these are expected to be sealed in the next few months. These patents are currently being examined in other major markets.

Vice President of Intellectual Property for Alchemia, Michael West, said, “This patent family provides legal protection for Alchemia’s processes for the synthesis of fondaparinux sodium through to 6 September 2022. These patents and the corresponding applications in other jurisdictions provide a good framework to protect our industrial synthesis of fondaparinux. We are looking forward to the successful US launch of the drug with our marketing partner Dr Reddy’s Inc.”

Alchemia and its manufacturing partner Dr Reddy’s Limited (NYSE:RDY) have made significant progress towards commercialization of fondaparinux, with approval and launch expected in the first half of 2009, depending on review time at the FDA.

http://www.alchemia.com.au

1
May

 

Medical Patent News

ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, unveiled today its DepoVax platform, a novel depot vaccine delivery system used to increase the efficacy and strength of vaccines. IVT has filed additional patents to protect the DepoVax concept.

“The results from our preclinical studies demonstrate that DepoVax is highly effective with a single dose,” remarked Marc Mansour, vice president of research and development at IVT. “DepoVax is superior to conventional vaccine formulations in its ability to raise strong cellular and humoral immune responses to a variety of antigens, a hallmark of IVT’s vaccine formulations.”

DepoVax has been tested in pandemic influenza and therapeutic cancer models. The research shows DepoVax-vaccines deliver effective, long lasting results with only one dose.

DepoVax vaccines are readily amenable to commercialization. They can be manufactured in large batches, and are well suited for large scale distribution and long term storage. DepoVax vaccines are packaged and stored in a dry form, ensuring the stability of antigens which can otherwise be unstable in aqueous formulations. DepoVax vaccines are also easy to administer by health care practitioners, an important consideration for immunization programs targeting infectious diseases in a population.

“Our patented technology offers a dramatic boost to the effectiveness of existing vaccines,” said Randal Chase, president and CEO of IVT. “An effective and easy-to-administer DepoVax vaccine would be a valuable tool for health authorities dealing with a pandemic and we are planning to take this into the clinic as soon as possible.”

http://www.immunovaccine.com

25
Apr

 

Medical Patent News

Latona Life Sciences Inc. announced today that it has entered into two agreements for the acquisition of patent rights and orphan drug status to a novel late-stage drug, trademarked “Oralgam,” for the treatment of Juvenile and Adult Rheumatoid Arthritis.

Latona has entered into a licensing agreement to acquire the patent rights to Oralgam with Research Corporation Technologies, Inc., of Tucson, Arizona. Under the terms of this agreement, Latona will acquire the exclusive worldwide rights to Oralgam for the treatment of Adult Rheumatoid Arthritis and the treatment of auto-immune induced hearing loss.

Latona has also entered into a purchase and sale agreement to acquire the Orphan Drug Status, clinical data set and trademark to Oralgam with Protein Therapeutics Inc. of Tucson, Arizona. Under the terms of this agreement Latona will acquire the Orphan Drug Status to Oralgam for the treatment of Juvenile Rheumatoid Arthritis, GI Dysfunction in Autism and Dermatomyostis.

“Latona is extremely pleased to acquire the worldwide rights to Oralgam,” stated Joseph Koziak, CEO of Latona. “We believe that Oralgam has the potential to provide significant relief to those who suffer from Arthritis and potential other auto-immune disorders.”

Oralgam is a late Phase II drug used for the treatment of immune mediated diseases. A novel product, Oralgam has shown efficacy in the treatment of juvenile arthritis in patients who have had limited success with other known pharmaceutical treatments. A platform technology, Oralgam is expected to be clinically tested in other immune mediated diseases.

http://www.latonalifesciences.com

25
Apr

 

Medical Patent News

LifeSync Corporation, a wholly owned subsidiary of GMP Companies, Inc., announced it has entered into a non-exclusive sublicense with Triage Wireless Inc. for LifeSync’s patent portfolio associated with the digital, wireless communication of patient vital signs.

This sublicense will allow Triage Wireless the right to utilize LifeSync’s technologies in connection with patient-worn multi-parameter monitors and associated bedside or mobile displays.

Shelley Hartman, President of LifeSync Corp, said, “We are delighted to enter into this sublicense with Triage Wireless. Triage is clearly a leading innovator in the development of wireless multi-parameter products designed to improve patient outcomes.”

LifeSync has developed and commercialized a wireless ECG data communication system for use in medical facilities under an exclusive license agreement from Motorola Inc. LifeSync intends to grant sublicenses for this intellectual property to third parties for uses that LifeSync does not intend to internally develop and commercialize.

http://www.lifesynccorp.com

24
Apr

 

Medical Patent News

Signalife, Inc. has announced that the United States Patent and Trademark Office has awarded the Company a new and important patent entitled “System For, And Method Of, Monitoring Heartbeats Of A Patient”. The patent, which covers 37 claims, will enhance the Company’s ability to develop new proprietary products.

Patent attorneys from Fulwider & Patton supervised and executed the patent application along with Chief Technology Officer Budimir S. Drakulic — the inventor of the patented technology. The new patent is owned by Signalife, Inc. In conjunction with the Patent Office’s granting of the patent, the Company will now evaluate whether or not it will file a continuation or continuation-in-part application for the purpose of pursuing additional claim coverage in the technology that may have occurred since the time of the original application.

Budimir S. Drakulic called the patent-issuance-development a “major milestone in the continued proliferation and protection of the Company’s core technologies and products.” Dr. Drakulic continued to say that issued patents together with significant patent portfolio already submitted to the United States Patent Office and two Frost & Sullivan technology awards represent major achievements for a young medical device company.

The Company currently has several additional patents pending before the United States Patent and Trademark Office covering a wide array of cardiac technologies and products. Dr. Drakulic stated that he is “confident the Company will continue to be successful in obtaining approvals for pending patents of its technologies and products.”

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

http://www.signalife.com

24
Apr

 

Medical Patent News

StemCells, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,361,505 with broad claims covering human neural stem cells derived from any tissue source, including embryonic, fetal, juvenile, or adult tissue. The ‘505 patent is exclusively licensed to StemCells.

“The issuance of this patent rounds out and strengthens our neural stem cell portfolio, which we believe is unparalleled in its breadth, depth and completeness,” said Martin McGlynn, President and CEO of StemCells, Inc. “We are confident that any third party wishing to commercialize neural stem cells as potential therapeutics or to use them as drug screening tools will have to seek a license from us irrespective of how they derive the cells. We have already granted licenses to several companies and are currently considering licensing others.”

StemCells, Inc., including its wholly-owned subsidiary, StemCells California, Inc., owns or has exclusive rights to more than 50 issued or allowed U.S. patents and more than 150 granted or allowed non-U.S. patents. Most of these have application to the selection, expansion or use of neural stem cells, and include claims which cover compositions of matter, methods of identifying, isolating and enriching neural stem and progenitor cell populations, and methods of using these cells for therapeutic applications as well as for drug discovery and screening. The Company has patent protection for the manufacture and use of its HuCNS-SC human neural stem cells through to the year 2024, even without relying on patent term extensions. Some of the Company’s other composition of matter patents, such as U.S. Patent Number 7,153,686 claim certain populations of enriched HuCNS-SC cells discovered by StemCells scientists. The Company has granted licenses to a number of companies in the neural stem cell field for limited purposes, including the U.S.-based BioWhittaker, Inc. (now part of the Swiss-based Lonza Group), UK-based ReNeuron Group plc, and Canadian-based Stem Cell Therapeutics Corp. and StemCell Technologies.

http://www.stemcellsinc.com